{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:10:42Z","timestamp":1774620642028,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12883-w","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T17:24:59Z","timestamp":1771694699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy and safety of selective COX-2 inhibitors and non-steroidal anti-inflammatory drugs in the treatment of COVID-19 patients: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixv","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"12883_CR1","doi-asserted-by":"crossref","unstructured":"Deng SQ, Peng HA-O. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. 575. https:\/\/pubmed.ncbi.nlm.nih.gov\/32093211\/.","DOI":"10.3390\/jcm9020575"},{"key":"12883_CR2","doi-asserted-by":"crossref","unstructured":"Hu BA-O, Guo HA-O, Zhou PA-O, Shi ZA-OX. Characteristics of SARS-CoV-2 and COVID-19.","DOI":"10.1038\/s41579-020-00459-7"},{"key":"12883_CR3","doi-asserted-by":"crossref","unstructured":"Chilamakuri R, Agarwal SA-O. COVID-19: characteristics and therapeutics. 206. http:\/\/pubmed.ncbi.nlm.nih.gov\/33494237\/.","DOI":"10.3390\/cells10020206"},{"key":"12883_CR4","unstructured":"Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2."},{"issue":"1","key":"12883_CR5","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S1473-3099(22)00433-9","volume":"23","author":"N Perico","year":"2023","unstructured":"Perico N, Cortinovis M, Suter F, Remuzzi G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect Dis. 2023;23(1):e22\u201333.","journal-title":"Lancet Infect Dis"},{"key":"12883_CR6","doi-asserted-by":"crossref","unstructured":"Hong W, Chen Y, You K, Tan S, Wu F, Tao J, et al. Celebrex adjuvant therapy on coronavirus disease 2019: an experimental study.","DOI":"10.1101\/2020.05.05.20077610"},{"key":"12883_CR7","unstructured":"Suter F, Consolaro E, Pedroni S, Moroni C, Past\u00f2 E, Paganini MV, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study."},{"key":"12883_CR8","doi-asserted-by":"crossref","unstructured":"El-Malah AA, Gineinah MM, Deb PK, Khayyat AN, Bansal M, Venugopala KN, et al. Selective COX-2 inhibitors: road from success to controversy and the quest for repurposing. Pharmaceuticals (Basel). 2022;15(7).","DOI":"10.3390\/ph15070827"},{"issue":"6","key":"12883_CR9","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s10787-024-01568-y","volume":"32","author":"N Mallah","year":"2024","unstructured":"Mallah N, Visos-Varela I, Takkouche B, Bugar\u00edn-Gonz\u00e1lez R, Pi\u00f1eiro-Lamas M, Herdeiro T, et al. The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study. Inflammopharmacology. 2024;32(6):3697\u2013705.","journal-title":"Inflammopharmacology"},{"issue":"5","key":"12883_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1039\/D1MD00280E","volume":"13","author":"M Ahmadi","year":"2022","unstructured":"Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med Chem. 2022;13(5):471\u201396.","journal-title":"RSC Med Chem"},{"issue":"8","key":"12883_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40261-021-01061-2","volume":"41","author":"HW Abdelwahab","year":"2021","unstructured":"Abdelwahab HW, Shaltout SW, Sayed Ahmed HA, Fouad AM, Merrell E, Riley JB, et al. Acetylsalicylic acid compared with Enoxaparin for the prevention of thrombosis and mechanical ventilation in COVID-19 patients: A retrospective cohort study. Clin Drug Investig. 2021;41(8):723\u201332.","journal-title":"Clin Drug Investig"},{"key":"12883_CR12","doi-asserted-by":"crossref","unstructured":"Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a danish nationwide cohort study. PLoS Med. 2020;17(9).","DOI":"10.1371\/journal.pmed.1003308"},{"key":"12883_CR13","doi-asserted-by":"crossref","unstructured":"Zekri-Nechar K, Barberan J, Zamorano-Leon JJ, Durban M, Andres-Castillo A, Navarro-Cuellar C, et al. Analysis of prior aspirin treatment on in-hospital outcome of geriatric COVID-19 infected patients. Medicina-Lithuania. 2022;58(11).","DOI":"10.3390\/medicina58111649"},{"issue":"10320","key":"12883_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","volume":"399","author":"Aspirin in patients admitted","year":"2022","unstructured":"Aspirin in patients admitted. To hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London England). 2022;399(10320):143\u201351.","journal-title":"Lancet (London England)"},{"key":"12883_CR15","doi-asserted-by":"crossref","unstructured":"Kim I, Yoon S, Kim M, Lee H, Park S, Kim W, et al. Aspirin is related to worse clinical outcomes of COVID-19. Medicina (Kaunas. Lithuania). 2021;57(9).","DOI":"10.3390\/medicina57090931"},{"key":"12883_CR16","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/eurheartj\/ehac544.2715","volume":"43","author":"F Santoro","year":"2022","unstructured":"Santoro F, Gil IN, Vitale E, Perez-Villacastin J, Fernandez-Ortiz A, Brunetti ND. Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: a propensity score-matched cohort analysis of the HOPE-COVID-19 registry. Eur Heart J. 2022;43:2715.","journal-title":"Eur Heart J"},{"issue":"4","key":"12883_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1213\/ANE.0000000000005292","volume":"132","author":"JH Chow","year":"2021","unstructured":"Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al. Aspirin use is associated with decreased mechanical Ventilation, intensive care unit Admission, and In-Hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg. 2021;132(4):930\u201341.","journal-title":"Anesth Analg"},{"issue":"11","key":"12883_CR18","doi-asserted-by":"publisher","first-page":"E4179","DOI":"10.1093\/cid\/ciaa1056","volume":"73","author":"HE Jeong","year":"2021","unstructured":"Jeong HE, Lee H, Shin HJ, Choe YJ, Filion KB, Shin J-Y. Association between nonsteroidal antiinflammatory drug use and adverse clinical outcomes among adults hospitalized with coronavirus 2019 in South korea: A nationwide study. Clin Infect Dis. 2021;73(11):E4179\u201388.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"12883_CR19","doi-asserted-by":"publisher","first-page":"e223890","DOI":"10.1001\/jamanetworkopen.2022.3890","volume":"5","author":"JH Chow","year":"2022","unstructured":"Chow JH, Rahnavard A, Gomberg-Maitland M, Chatterjee R, Patodi P, Yamane DP, et al. Association of early aspirin use with In-Hospital mortality in patients with moderate COVID-19. JAMA Netw Open. 2022;5(3):e223890.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"12883_CR20","doi-asserted-by":"publisher","first-page":"e0246825","DOI":"10.1371\/journal.pone.0246825","volume":"16","author":"TF Osborne","year":"2021","unstructured":"Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, R\u00f6\u00f6sli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the veterans health administration. PLoS ONE. 2021;16(2):e0246825.","journal-title":"PLoS ONE"},{"key":"12883_CR21","unstructured":"Baldia PH, Wernly B, Flaatten H, Fjolner J, Artigas A, Pinto BB, et al. The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trial. BMC Geriatr. 2022;22(1)."},{"key":"12883_CR22","doi-asserted-by":"crossref","unstructured":"Hong W, Chen Y, You K, Tan S, Wu F, Tao J, et al. Celebrex adjuvant therapy on coronavirus disease 2019: an experimental study. Front Pharmacol. 2020;11.","DOI":"10.3389\/fphar.2020.561674"},{"issue":"12","key":"12883_CR23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S2213-2600(22)00299-5","volume":"10","author":"JW Eikelboom","year":"2022","unstructured":"Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, et al. Colchicine and as Pirin in community patients witph COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respiratory Med. 2022;10(12):1160\u20138.","journal-title":"Lancet Respiratory Med"},{"issue":"12","key":"12883_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S2213-2600(22)00298-3","volume":"10","author":"JW Eikelboom","year":"2022","unstructured":"Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, et al. Colchicine and the combination of Rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respiratory Med. 2022;10(12):1169\u201377.","journal-title":"Lancet Respiratory Med"},{"issue":"3","key":"12883_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11739-021-02870-1","volume":"17","author":"F Formiga","year":"2022","unstructured":"Formiga F, Rubio-Rivas M, Maria Mora-Lujan J, Campos Escudero S, Madera Martinez RF, Mendez-Bailon M, et al. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 registry. Intern Emerg Med. 2022;17(3):761\u201375.","journal-title":"Intern Emerg Med"},{"issue":"13","key":"12883_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.2022.2910","volume":"327","author":"CA Bradbury","year":"2022","unstructured":"Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, et al. Effect of antiplatelet therapy on survival and organ Support-Free days in critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2022;327(13):1247\u201359.","journal-title":"JAMA"},{"key":"12883_CR27","doi-asserted-by":"crossref","unstructured":"Son M, Noh M-g, Lee JH, Seo J, Park H, Yang S. Effect of aspirin on coronavirus disease 2019 a nationwide case-control study in South Korea. Medicine. 2021;100(30).","DOI":"10.1097\/MD.0000000000026670"},{"issue":"6","key":"12883_CR28","doi-asserted-by":"publisher","first-page":"e24544","DOI":"10.1097\/MD.0000000000024544","volume":"100","author":"Q Liu","year":"2021","unstructured":"Liu Q, Huang N, Li A, Zhou Y, Liang L, Song X, et al. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine. 2021;100(6):e24544.","journal-title":"Medicine"},{"issue":"9","key":"12883_CR29","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1177\/08850666221093229","volume":"37","author":"AF Al Harthi","year":"2022","unstructured":"Al Harthi AF, Aljuhani O, Korayem GB, Altebainawi AF, Alenezi RS, Al Harbi S, et al. Evaluation of Low-Dose A`sp@irin use among critically ill `Patients with COVID-19: A multicenter propensity score matched study. J Intensive Care Med. 2022;37(9):1238\u201349.","journal-title":"J Intensive Care Med"},{"issue":"1","key":"12883_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","volume":"10","author":"LC Abu Esba","year":"2021","unstructured":"Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: A prospective cohort study. Infect Dis Therapy. 2021;10(1):253\u201368.","journal-title":"Infect Dis Therapy"},{"key":"12883_CR31","doi-asserted-by":"crossref","unstructured":"Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26(9).","DOI":"10.1016\/j.cmi.2020.06.003"},{"key":"12883_CR32","doi-asserted-by":"crossref","unstructured":"Gurbel PA, Bliden K, Walia N, Rapista N, Ens G, Barnes J, et al. Is low dose aspirin effective in reducing in-hospital clinical outcomes in patients with COVID-19? J Am Coll Cardiol. 2021;77(18):3083-.","DOI":"10.1016\/S0735-1097(21)04438-7"},{"issue":"16","key":"12883_CR33","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1007\/s11606-022-07701-3","volume":"37","author":"CM Hunt","year":"2022","unstructured":"Hunt CM, Efird JT, Redding TS, Thompson AD Jr., Press AM, Williams CD, et al. Medications associated with lower mortality in a SARS-CoV-2 positive cohort of 26,508 veterans. J Gen Intern Med. 2022;37(16):4144\u201352.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"12883_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/jcmm.16198","volume":"25","author":"S Yuan","year":"2021","unstructured":"Yuan S, Chen P, Li H, Chen C, Wang F, Wang DW. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. J Cell Mol Med. 2021;25(2):1263\u201373.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"12883_CR35","doi-asserted-by":"publisher","first-page":"e12743","DOI":"10.1002\/rth2.12743","volume":"6","author":"J Botton","year":"2022","unstructured":"Botton J, Semenzato L, Dupouy J, Dray-Spira R, Weill A, Saint-Lary O, et al. No association of low-dose aspirin with severe COVID-19 in france: A cohort of 31.1 million people without cardiovascular disease. Res Pract Thromb Haemostasis. 2022;6(4):e12743.","journal-title":"Res Pract Thromb Haemostasis"},{"issue":"1","key":"12883_CR36","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1038\/s41598-021-84539-5","volume":"11","author":"J Park","year":"2021","unstructured":"Park J, Lee SH, You SC, Kim J, Yang K. Non-steroidal anti-inflammatory agent use May not be associated with mortality of coronavirus disease 19. Sci Rep. 2021;11(1):5087.","journal-title":"Sci Rep"},{"issue":"7","key":"12883_CR37","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2665-9913(21)00104-1","volume":"3","author":"TM Drake","year":"2021","unstructured":"Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC clinical characterisation protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021;3(7):e498\u2013506.","journal-title":"Lancet Rheumatol"},{"key":"12883_CR38","doi-asserted-by":"crossref","unstructured":"Reese JT, Coleman B, Chan L, Blau H, Callahan TJ, Cappelletti L, et al. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. medRxiv: the preprint server for health sciences. 2021.","DOI":"10.1186\/s12985-022-01813-2"},{"issue":"11","key":"12883_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.arbres.2022.07.017","volume":"58","author":"A Lal","year":"2022","unstructured":"Lal A, Garces JPD, Bansal V, Tekin A, Zec S, Khanna AK, et al. Pre-hospital aspirin use and patient outcomes in COVID-19: results from the international viral infection and respiratory illness universal study (VIRUS). Arch Bronconeumol. 2022;58(11):746\u201353.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"12883_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11357-021-00499-8","volume":"44","author":"C Sullerot","year":"2022","unstructured":"Sullerot C, Bouiller K, Laborde C, Gilis M, F\u00e8vre A, Hacquin A, et al. Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia. GeroScience. 2022;44(2):573\u201383.","journal-title":"GeroScience"},{"key":"12883_CR41","doi-asserted-by":"crossref","unstructured":"Bruce E, Barlow-Pay F, Short R, Vilches-Moraga A, Price A, McGovern A, et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med. 2020;9(8).","DOI":"10.3390\/jcm9082586"},{"issue":"1","key":"12883_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-021-00689-y","volume":"6","author":"C Mura","year":"2021","unstructured":"Mura C, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R. Real-world evidence for improved outcomes with Histamine antagonists and aspirin in 22,560 COVID-19 patients. Signal Transduct Target Therapy. 2021;6(1):267.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"12883_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5492\/wjccm.v11.i2.92","volume":"11","author":"M Gogtay","year":"2022","unstructured":"Gogtay M, Singh Y, Bullappa A, Scott J. Retrospective analysis of aspirin\u2019s role in the severity of COVID-19 pneumonia. World J Crit Care Med. 2022;11(2):92\u2013101.","journal-title":"World J Crit Care Med"},{"issue":"4","key":"12883_CR44","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s40121-021-00527-2","volume":"10","author":"O Salva","year":"2021","unstructured":"Salva O, Doreski PA, Giler CS, Quinodoz DC, Guzman LG, Munoz SE, et al. Reversal of SARS-CoV2-Induced hypoxia by nebulized sodium ibuprofenate in a compassionate use program. Infect Dis Therapy. 2021;10(4):2511\u201324.","journal-title":"Infect Dis Therapy"},{"issue":"7","key":"12883_CR45","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1002\/cti2.1159","volume":"9","author":"SWX Ong","year":"2020","unstructured":"Ong SWX, Tan WYT, Chan YH, Fong SW, Renia L, Ng LF, et al. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin Translational Immunol. 2020;9(7):e1159.","journal-title":"Clin Translational Immunol"},{"issue":"7","key":"12883_CR46","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/annrheumdis-2020-219517","volume":"80","author":"AY Wong","year":"2021","unstructured":"Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an opensafely cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"12883_CR47","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/S2213-2600(23)00376-4","volume":"11","author":"FC Hall","year":"2023","unstructured":"Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, et al. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial. Lancet Respiratory Med. 2023;11(12):1064\u201374.","journal-title":"Lancet Respiratory Med"},{"key":"12883_CR48","first-page":"e081165","volume":"389","author":"S Ibrahim","year":"2025","unstructured":"Ibrahim S, Siemieniuk RAC, Oliveros MJ, Islam N, D\u00edaz Martinez JP, Izcovich A, et al. Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis. BMJ (Clinical Res ed). 2025;389:e081165.","journal-title":"BMJ (Clinical Res ed)"},{"key":"12883_CR49","doi-asserted-by":"crossref","unstructured":"Alhamlan FS, Al-Qahtani AA. SARS-CoV-2 variants: genetic insights, epidemiological tracking, and implications for vaccine strategies. Int J Mol Sci. 2025;26(3).","DOI":"10.3390\/ijms26031263"},{"issue":"1","key":"12883_CR50","doi-asserted-by":"publisher","first-page":"2485840","DOI":"10.1080\/21645515.2025.2485840","volume":"21","author":"A Akingbola","year":"2025","unstructured":"Akingbola A, Adewole O, Adegbesan A, Peters F, Odukoya T, Aremu O, et al. From Wuhan to Omicron K.P2 strain: A comprehensive review of SARS-CoV-2 phylogeny and public health implications of the latest booster vaccine. Hum Vaccines Immunotherapeutics. 2025;21(1):2485840.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"12883_CR51","unstructured":"Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the treatment of COVID-19: review of literature to propose repositioning of celecoxib for randomized controlled studies."},{"issue":"3","key":"12883_CR52","doi-asserted-by":"publisher","first-page":"e25734","DOI":"10.1016\/j.heliyon.2024.e25734","volume":"10","author":"S Moshawih","year":"2024","unstructured":"Moshawih S, Jarrar Q, Bahrin AA, Lim AF, Ming L, Goh HP. Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies. Heliyon. 2024;10(3):e25734.","journal-title":"Heliyon"},{"key":"12883_CR53","doi-asserted-by":"crossref","unstructured":"Terrier O, Dilly S, Pizzorno A, Chalupska D, Humpolickova J, Bou\u0159a E, et al. Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus. Molecules. 2021;26(9).","DOI":"10.3390\/molecules26092593"},{"issue":"1","key":"12883_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2009.03.007","volume":"258","author":"S Bancos","year":"2009","unstructured":"Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol. 2009;258(1):18\u201328.","journal-title":"Cell Immunol"},{"issue":"1","key":"12883_CR55","doi-asserted-by":"publisher","first-page":"9606","DOI":"10.1038\/s41598-021-88313-5","volume":"11","author":"KK Oh","year":"2021","unstructured":"Oh KK, Adnan M, Cho DH. Network Pharmacology approach to Decipher signaling pathways associated with target proteins of NSAIDs against COVID-19. Sci Rep. 2021;11(1):9606.","journal-title":"Sci Rep"},{"key":"12883_CR56","unstructured":"Das UN. Bioactive lipids in COVID-19-further evidence."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12883-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12883-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12883-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:05:18Z","timestamp":1774616718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12883-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12883"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12883-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"656"}}